One assignee holds 362 of the 762 records in scope, far ahead of the rest of the ranked field of 88 companies. The next four filers combine with the leader for 491 records, or 64.4% of all records in scope. Below the top ten — which together hold 591 records, 77.6% of the total — the field thins quickly into single-digit filers, so due diligence should focus heavily on the leading handful of assignees rather than treating this as evenly distributed.

Accelerated blood clearance (ABC) is the phenomenon where a first dose of a PEGylated or lipid nanoparticle formulation triggers antibody or complement responses that cause a second dose to be cleared from circulation much faster, undermining repeat-dosing efficacy. It is a central reactogenicity concern for LNP-based vaccines and therapeutics that require multiple doses. Several of the most-cited records in this landscape, including the top-cited WO2017099823A1, explicitly claim compositions designed to avoid triggering this response.

The classification data suggests polymer-chemistry claims — covering condensation polymers (C08G), acyclic and carbocyclic compounds (C07C), and polymer compositions (C08L) — appear on only 5-11% of the 762 records in scope, well below the 88.3% carrying medicinal-preparation claims. That gap does not guarantee an open path, since some of the largest filers likely hold foundational lipid-composition claims that touch adjacent polymer chemistry, but it does indicate the PEG-alternative space is comparatively less densely claimed and worth a focused freedom-to-operate check.